99% Savings - Buy Just @1 Rs X
Labebet 50 Tablet is a prescription drug, available for use as Tablet. High BP are some of its major therapeutic uses. Secondary and off-label uses of Labebet 50 Tablet have also been mentioned below.
The correct dosage of Labebet 50 Tablet depends on the patient's age, gender, and medical history. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. Refer to the dosage section for a detailed discussion.
While these are the most often observed Labebet 50 Tablet side effects, there are can be others also. These have been listed below. These side effects of Labebet 50 Tablet are usually temporary and subside with the completion of treatment. However, if these continue for a longer time, consult your doctor right away.
In addition, Labebet 50 Tablet's effect is Severe during pregnancy and Mild for lactating mothers. Further, the section on Labebet 50 Tablet related warnings talks about Labebet 50 Tablet's effects on the liver, heart and kidney.
Individuals suffering from medical conditions like Diabetes, Asthma, COPD (Chronic Obstructive Pulmonary Disease) must refrain from the use of Labebet 50 Tablet since this can cause severe adverse effects. Other contraindications of Labebet 50 Tablet have been discussed in the sections ahead.
Additionally, Labebet 50 Tablet may also adversely react with other medicines. See below for a complete list.
Along with the above-mentioned precautions, remember that taking Labebet 50 Tablet is considered not safe while driving, and is not addictive.
Labebet 50 Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Geriatric |
|
Adult |
|
Is the use of Labebet 50 Tablet safe for pregnant women?
Labebet shows severe side effect on pregnant women. For this reason, pregnant women should only take it after taking medical advice.
Is the use of Labebet 50 Tablet safe during breastfeeding?
Labebet has been seen to have minimal side effects on breastfeeding women.
What is the effect of Labebet 50 Tablet on the Kidneys?
Labebet is completely safe for kidneys.
What is the effect of Labebet 50 Tablet on the Liver?
Side effects of Labebet rarely affect the liver.
What is the effect of Labebet 50 Tablet on the Heart?
Labebet may have mild side effects on the heart. Most people will never see any effect on the heart.
If you are suffering from any of the following diseases, you should not take Labebet 50 Tablet unless your doctor advises you to do so -
Is this Labebet 50 Tablet habit forming or addictive?
Labebet 50 Tablet is not addictive in nature.
Is it safe to drive or operate heavy machinery when consuming?
You may feel sleepy or tired after taking Labebet 50 Tablet. So it is best to avoid driving.
Is it safe?
Labebet 50 Tablet is safe but it is important to consult a doctor before taking it.
Is it able to treat mental disorders?
No, Labebet 50 Tablet is not used to treat mental disorders.
Interaction between Food and Labebet 50 Tablet
When consumed with certain foods, Labebet 50 Tablet may take longer to have an effect. Contact your doctor about this.
Interaction between Alcohol and Labebet 50 Tablet
Consult your doctor before consuming alcohol while taking Labebet 50 Tablet as it can have severe side effects.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Trandate® (labetalol hydrochloride)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 151
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 735-737